Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Virtual Congress 2020

AstraZeneca - Current status and future directions for immunotherapy in hepatocellular carcinoma

IO combinations in first-line advanced HCC: Current evidence and ongoing trials

Date

14 Sep 2020

Session

AstraZeneca - Current status and future directions for immunotherapy in hepatocellular carcinoma

Presenters

Peter Galle

Authors

P.R. Galle

Author affiliations

  • I. Dept. Of Internal Medicine, Universitätsmedizin Mainz, 55131 - Mainz/DE

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Login

Resources from the same session

Welcome and introduction

Presenter: Ghassan Abou-Alfa

Session: AstraZeneca - Current status and future directions for immunotherapy in hepatocellular carcinoma

Resources:

Webcast

Brief overview of immuno-oncology in HCC

Presenter: Ghassan Abou-Alfa

Session: AstraZeneca - Current status and future directions for immunotherapy in hepatocellular carcinoma

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.